Form 4: Supernus CEO Exercises Options, Sells Shares

Supernus Pharmaceuticals CEO Jack Khattar exercised stock options and sold a portion of the acquired shares under a pre-arranged trading plan.

Summary

• Jack A. Khattar, President, CEO, and Director of Supernus Pharmaceuticals, Inc. (SUPN), exercised employee stock options for a total of 201,250 shares of common stock.
• The options were exercised at prices of $12.98 per share (120,000 shares) and $25.30 per share (81,250 shares).
• Concurrently, Mr. Khattar sold 140,000 shares of common stock on the open market.
• The shares were sold at weighted average prices ranging from $40.24 to $43.12 per share, with individual transaction prices between $40.00 and $43.56.
• All reported transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on September 15, 2022.
• Following these transactions, Mr. Khattar's direct beneficial ownership of Supernus common stock increased by 61,250 shares, totaling 1,069,933 shares.
• Indirect beneficial ownership remains at 1,005,600 shares held by the KBT Trust.

Sentiment

Score: 7

Explanation: The CEO exercised a significant number of options at lower prices and sold a portion at much higher market prices, indicating a profitable transaction. The net effect is an increase in direct beneficial ownership, which can be seen as a positive signal of continued alignment with shareholder interests. The use of a 10b5-1 plan suggests these were pre-planned financial management activities rather than reactive trades.

Positives

• The CEO exercised a significant number of options at prices substantially below the market sale prices, indicating a profitable transaction for the insider.
• The net effect of the transactions is an increase in the CEO's direct beneficial ownership by 61,250 shares, which can be viewed as a positive signal of continued alignment with shareholder interests.
• Transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which mitigates concerns about opportunistic trading based on non-public information.

Negatives

• The sale of 140,000 shares by a key executive, even if pre-planned, could be perceived negatively by some investors as a reduction in personal stake.

Future Outlook

N/A

Industry Context

N/A

Related Party Transactions

• Indirect beneficial ownership of 1,005,600 shares is held by the KBT Trust, which is likely a related party to the reporting person.

Stakeholder Impact

• Shareholders: The net increase in direct beneficial ownership by the CEO may be viewed positively as it indicates continued investment in the company. However, the sale of a significant number of shares, even under a 10b5-1 plan, could lead to mixed perceptions.
• Employees: No direct impact on employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Key Dates

Recommendation

The filing details routine insider transactions under a pre-established 10b5-1 plan, involving the exercise of options and subsequent sale of a portion of shares. While the CEO increased their direct beneficial ownership, the sale of a significant number of shares, even if pre-planned, does not provide a strong signal for a 'buy' or 'sell' recommendation. It primarily reflects personal financial management rather than a change in company fundamentals or outlook. Investors should consider broader company performance and market conditions.

Keywords

Supernus Pharmaceuticals, SUPN, Insider Trading, Form 4, Stock Options, CEO, Jack Khattar, Share Sale, Equity, Beneficial Ownership, 10b5-1 Plan